Skip to main content
Gene Therapy OversightCRISPR· 6 min read· in Science

Shanghai Dismisses Scientists Following Child's Death in Unapproved Brain Gene-Editing Trial

Two leading researchers were fired and barred from state science programs after an investigation revealed severe safety and ethical lapses in a fatal 2025 CRISPR trial. The team concealed the six-year-old patient's death and accepted over $1 million in funding and gifts from her family.

By Karim Mansour

Share this story

Listen

Shanghai authorities have dismissed two leading scientists and penalized several hospital officials following an investigation into the death of a six-year-old girl during an experimental brain gene-editing trial. The disciplinary actions mark the conclusion of a high-profile probe into severe clinical misconduct.[1][2]

The municipal investigation team released its findings on November 13, detailing extensive ethical and safety lapses at Shanghai Jiao Tong University School of Medicine and its affiliated Xinhua Hospital. The report outlined a pattern of regulatory evasion throughout the trial's lifecycle.[3][5]

The child, who suffered from a rare neurodevelopmental disorder, died in March 2025, just days after receiving a custom CRISPR-derived base editor injection into her spinal fluid. The procedure was the world's first known attempt to edit genes inside a living human brain.[2][4]

The Investigation Findings

Investigators concluded that the research team, led by Qiu Zilong and Yang Kan, bypassed critical safety protocols prior to the human trial. Crucially, they failed to share concerning non-human primate toxicology data with the clinical lead overseeing the patient's care.[2][6]

The ethics committee at Xinhua Hospital approved the study in January 2025 despite this glaring lack of sufficient safety evidence. Furthermore, the consent forms provided to the family did not prominently state the risk of death associated with the experimental procedure.[2]

Authorities also uncovered significant financial irregularities surrounding the unauthorized trial. The investigation noted that the patient's family contributed 5.337 million yuan, or approximately $800,000, directly toward the research project in hopes of securing a cure.[1][2]

Timeline of the unauthorized clinical trial and subsequent investigation.

In addition to the project funding, the researchers accepted roughly 1.06 million yuan in personal cash and gifts from the family. These illicit payments, which included expensive liquor and electronics, have since been returned or surrendered to authorities.[2]

The Experimental Treatment

The patient had Snijders Blok-Campeau syndrome, a rare genetic condition caused by mutations in the CHD3 gene. The disorder is characterized by severe intellectual disability and speech impairment, and it currently has no approved treatments available anywhere in the world.[2][3]

Driven by desperation, the family approached Qiu in July 2023, hoping his laboratory could design a customized therapy. Their goal was to correct the single faulty letter in the girl's DNA code that was responsible for her debilitating condition.[1][2]

The research team utilized a base editor, a highly precise CRISPR-derived tool designed to chemically convert one DNA letter into another. Unlike traditional CRISPR systems, base editors achieve this without creating potentially dangerous double-strand breaks in the genome.[2]

To deliver the editing machinery into the brain cells, the scientists packaged the genetic instructions inside two adeno-associated virus vectors. While common in gene therapy, this delivery method is immunologically complex and carries significant risks at high doses.[1][2]

The child received the experimental injection directly into her spinal fluid on March 24, 2025. Her condition rapidly deteriorated following the procedure, and despite intensive medical intervention, she died seven days later on March 31.[2]

An emergency ethics review convened on April 2 attributed her death to thrombotic microangiopathy. This severe immune and clotting complication is increasingly recognized as a fatal risk associated with high-dose viral vector therapies.[2]

The experimental therapy utilized a CRISPR-derived base editor delivered via viral vectors.

Publication and Cover-Up

Despite the fatal outcome of the human trial, Qiu's team proceeded to publish their preclinical results in the prestigious journal Nature nearly a year later, in February 2026. The published paper highlighted the technique's potential for human application.[2]

The Nature publication omitted any mention of the child's death, or the fact that a human trial had even taken place. The researchers also failed to disclose the liver and kidney damage observed during their earlier non-human primate safety tests.[2][3]

While the Shanghai municipal investigation found no outright data fabrication in the Nature paper, it identified significant academic irregularities. These included discrepancies in the reported methods and the unexplained repeated presentation of data from a single batch.[1][3]

The fatal trial remained entirely hidden from the broader scientific community for more than a year. It was finally exposed in July 2026, when a joint investigation by Science and Retraction Watch brought the tragedy to public attention and prompted the official probe.[1][2]

Penalties and Institutional Fallout

As a direct result of the probe, Qiu and Yang were formally dismissed from their academic and clinical positions. The disciplinary action severs their ties with Shanghai Jiao Tong University School of Medicine and its affiliated research institutes.[3][6]

Both scientists were barred for five years from participating in state-funded science programs, applying for grants, or competing for national research awards. They have also been entered into a national database tracking serious research integrity violations.[1][2]

Financial contributions and illicit gifts accepted by the research team.

The clinical study's lead investigator at Xinhua Hospital, surnamed Yu, was removed as head of the research department and demoted. Investigators determined he failed to adequately review the preclinical safety data before proceeding with the human injection.[2][3]

The head of the hospital's ethics committee office, surnamed Shi, was also demoted for his role in the oversight failure. The committee had approved the high-risk study without demanding sufficient toxicology evidence from the research team.[2]

"The investigation found that Qiu's team from the Songjiang Research Institute and relevant personnel from Xinhua Hospital did not strictly adhere to relevant regulations during the research," the municipal task force stated in its official release.[3]

Consequently, Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, and Songjiang District Central Hospital were summoned for talks. The institutions were issued administrative penalties and ordered to implement comprehensive supervisory reforms to prevent future ethical breaches.[1][3]

Regulatory Implications

The incident highlights critical vulnerabilities in China's dual-track regulatory system, which governs how experimental medical treatments transition from the laboratory to human patients. The framework relies heavily on local oversight rather than centralized national approval.[2]

Under this system, doctors at major hospitals can test novel therapies through investigator-initiated trials after securing local ethical review. They do not require prior clearance from the national drug administration to administer experimental treatments to desperate patients.[2]

Illustration: The Shanghai Municipal Health Commission has launched a special inspection campaign into emerging biomedical research.

While this decentralized approach has accelerated domestic biotech development and expanded access to experimental care, it places immense responsibility on hospital ethics committees. These local boards are often ill-equipped to evaluate the complex safety profiles of emerging genetic technologies.[2][7]

In response to the tragedy, the Shanghai Municipal Health Commission announced a special inspection campaign. The initiative will target all clinical research within the municipality that utilizes emerging biomedical technologies, aiming to close existing regulatory loopholes.[2]

The commission cited the inherently high risks associated with cell and gene therapies as the primary driver for the crackdown. Officials emphasized the urgent need for stricter oversight and standardized safety protocols at the local hospital level.[2][5]

The case has also drawn intense international scrutiny, prompting calls from global bioethicists for tighter standards. Experts argue that clinical data generated outside of centralized regulatory frameworks must be subjected to rigorous independent verification before publication.[2][7]

Key points

  1. Shanghai authorities dismissed researchers Qiu Zilong and Yang Kan following the death of a six-year-old girl in an experimental brain gene-editing trial.
  2. The investigators found the team bypassed safety protocols, ignored primate toxicology warnings, and accepted over $1 million in funding and gifts from the family.
  3. The researchers published their preclinical results in Nature nearly a year later without disclosing the child's death or the adverse animal data.
  4. The incident has prompted the Shanghai Municipal Health Commission to launch a targeted inspection campaign of clinical research involving emerging biomedical technologies.

What we don’t know

  • It remains unclear whether the researchers will face criminal charges beyond their academic dismissals and administrative penalties.
  • The exact nature of the administrative penalties levied against the involved hospitals has not been fully detailed by the municipal task force.
  • It is unknown how the journal Nature will address the identified academic irregularities and omissions in the researchers' February 2026 publication.

How we got here

  1. July 2023

    The patient's family approaches researcher Qiu Zilong to design a custom gene-editing treatment.

  2. January 2025

    Xinhua Hospital's ethics committee approves the experimental study despite insufficient safety evidence.

  3. March 2025

    The child receives the viral vector injection and dies seven days later from thrombotic microangiopathy.

  4. February 2026

    The research team publishes preclinical results in Nature, omitting the human trial and the child's death.

  5. July 2026

    A joint investigation by Science and Retraction Watch exposes the fatal trial to the public.

  6. November 2026

    Shanghai authorities release their findings, dismissing the researchers and penalizing hospital officials.

Municipal Investigators 60%Bioethics Community 40%
Municipal Investigators
Shanghai authorities emphasize the need for strict adherence to clinical regulations and ethical oversight.
Bioethics Community
Global bioethicists warn of the dangers inherent in investigator-initiated trials for emerging genetic therapies.

Perspectives this story doesn't cover

  • The patient's family
  • Nature journal editorial board

Sources

Source coverage

7 outlets

2 viewpoints surfaced

Municipal Investigators 60%Bioethics Community 40%
  1. [1]South China Morning PostBioethics Community

    Chinese scientists fired after child dies in world's first brain gene-editing attempt

    Read on South China Morning Post →
  2. [2]Sixth ToneMunicipal Investigators

    Shanghai Sacks Two Scientists Over Child's Death in Gene Trial

    Read on Sixth Tone →
  3. [3]China DailyMunicipal Investigators

    Shanghai releases investigation results on gene-editing research incident

    Read on China Daily →
  4. [4]Fierce BiotechBioethics Community

    Chinese scientists fired after child dies in gene editing study: report

    Read on Fierce Biotech →
  5. [5]City News ServiceMunicipal Investigators

    Shanghai Dismisses Researchers After Probe Into Child's Death in Gene Therapy Study

    Read on City News Service →
  6. [6]Caixin GlobalBioethics Community

    Shanghai Fires Gene-Editing Researcher After Child's Death

    Read on Caixin Global →
  7. [7]Hindustan TimesBioethics Community

    China finds ethical flaw in gene-editing trial that led to child's death; two researchers fired

    Read on Hindustan Times →
Listen

Comments

Stay informed

Every angle. Every day.

Get Science stories with full source coverage and perspective breakdowns, free every day.